Net sales for the interim period were \u00a570,749 million, up 2.5% year over year. Operating income was \u00a52,162 million, down 67.5% YoY. Ordinary income was \u00a53,006 million, down 58.5% YoY. Net income attributable to owners of the parent was \u00a51,136 million, down 64.1% YoY. Full-year guidance unchanged. Proposed dividends: an interim dividend of \u00a545 per share at the end of the second quarter and a \u00a561 per share forecast at the end of the third quarter, for a total of \u00a5106 per share for the year. Segments remain robust domestically, but profits were eroded by international and Cairo-related pressures. Notable items include product recall-related losses and costs related to plant consolidation.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4967","jir_company_name":"Kobayashi Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4967-20260806-01.pdf","jir_short_summary":"Net sales for the interim period were \u00a570,749 million, up 2.5% year over year. Operating income was \u00a52,162 million, down 67.5% YoY. Ordinary income was \u00a53,006 million, down 58.5% YoY. Net income attributable to owners of the parent was \u00a51,136 million, down 64.1% YoY. Full-year guidance unchanged. Proposed dividends: an interim dividend of \u00a545 per share at the end of the second quarter and a \u00a561 per share forecast at the end of the third quarter, for a total of \u00a5106 per share for the year. Segments remain robust domestically, but profits were eroded by international and Cairo-related pressures. Notable items include product recall-related losses and costs related to plant consolidation.","jir_summary":"### Overview of Results\nNet sales for the interim period reached \u00a570,749 million, marking a 2.5% year-over-year increase, while operating income declined sharply to \u00a52,162 million. Domestic segments remained solid due to new product effects, but international operations saw declines in revenue and profit due to factors such as U.S. supply issues, pressuring overall profitability. Interim net income also fell to \u00a51,136 million. Full-year guidance remains unchanged.\n\n### Outlook and Key Items\nKey factors behind the substantial YoY decline include the occurrence of extraordinary gains and losses, foreign exchange impacts, and higher energy costs. Notable items include compensation and recall costs related to products containing red yeast rice, plant consolidation costs, and losses from asset disposals by subsidiaries. The full-year earnings forecast for 2026 remains as stated in the financial summary. Going forward, overseas market trends and risk management of raw materials and logistics are expected to be key to the earnings recovery.","jir_financial_highlights":"Sales: 70,749 (YoY +2.5%)\nOperating income: 2,162 (YoY \u25b367.5%)\nOrdinary income: 3,006 (YoY \u25b358.5%)\nNet income attributable to owners of the parent: 1,136 (YoY \u25b364.1%)\nEarnings per share: 15.29 (Unknown)\nEquity ratio: 82.9 (Year-end comparison \u25b2 (change in value unknown))","jir_category":"","jir_hashtags":"#KobayashiPharmaceutical, #FinancialResults, #InterimPeriod, #SegmentedRevenue","jir_key_figures":"Sales: \u00a570,749 million (YoY +2.5%)\nOperating income: \u00a52,162 million (YoY \u25b367.5%)\nNet income attributable to owners of the parent: \u00a51,136 million (YoY \u25b364.1%)","jir_meta_title":"Kobayashi Pharmaceutical: 2Q 2026 Interim Consolidated Results \u2014 Revenue Up, Large Profit Decline; Full-Year Guidance Unchanged","jir_meta_description":"Analysis of Kobayashi Pharmaceutical's 2Q 2026 interim consolidated financial results. Net sales \u00a570,749 million, operating income \u00a52,162 million, net income \u00a51,136 million. Overview of overseas markets, notable items, and whether full-year guidance changed.","jir_og_title":"Kobayashi Pharmaceutical 2Q Interim Results \u2014 Revenue Up, Profit Pressure","jir_og_description":"Kobayashi Pharmaceutical's interim period results show revenue growth but significant profit decline. Discusses impact of overseas markets and special losses. Full-year guidance unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7982,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-97500","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n